Sugammadex Reduced the Incidence of Postoperative Pulmonary Complications in Susceptible Patients Identified by ARISCAT Risk Index: Systematic Review and Meta-analysis

Introduction The efficacy of sugammadex on postoperative pulmonary complications (PPCs) in susceptible patients, compared with neostigmine, remains indeterminate. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Group Investigators proposed a risk index for the early identific...

Full description

Saved in:
Bibliographic Details
Published in:Advances in therapy 2023-09, Vol.40 (9), p.3784-3803
Main Authors: Bai, Yun-Xiao, Han, Jing-Jing, Liu, Jie, Li, Xia, Xu, Zhen-Zhen, Lv, Yong, Liu, Ke-Xuan, Wu, Qing-Ping
Format: Article
Language:English
Subjects:
Cardiology
Endocrinology
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Original Research
Pharmacology/Toxicology
Rheumatology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The efficacy of sugammadex on postoperative pulmonary complications (PPCs) in susceptible patients, compared with neostigmine, remains indeterminate. The Assess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Group Investigators proposed a risk index for the early identification of susceptible patients, with excellent externally validated discrimination ability. Meta-analytical techniques were applied to evaluate the efficacy of sugammadex on PPCs in patients with ARISCAT-defined risk factors. Methods The study is registered on PROSPERO, number CRD42021261156. We searched PubMed, Scopus, Embase, Cochrane library, GreyNet, and OpenGrey for eligible randomized controlled trials (RCTs) without restricting the language or year of publication. Results Twelve RCTs consisting of 1182 patients susceptible to PPCs were included. A robust reduction was observed on the incidence of PPCs in susceptible patients who received sugammadex [RR 0.66; 95% CI (0.54, 0.80), p  
ISSN:0741-238X
1865-8652
DOI:10.1007/s12325-023-02535-9